• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Escherichia Coli Infections - Pipeline Review, H2 2012 Product Image

Escherichia Coli Infections - Pipeline Review, H2 2012

  • Published: October 2012
  • 65 pages
  • Global Markets Direct

Escherichia Coli Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Escherichia Coli Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Escherichia Coli Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Escherichia Coli Infections.
- A review of the Escherichia Coli Infections READ MORE >

2
List of Tables 5
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Escherichia Coli Infections Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Escherichia Coli Infections 8
Escherichia Coli Infections Therapeutics under Development by Companies 10
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Escherichia Coli Infections Therapeutics – Products under Development by Companies 16
Companies Involved in Escherichia Coli Infections Therapeutics Development 17
Piramal Healthcare Limited 17
Nabi Biopharmaceuticals 18
Wockhardt Limited 19
Paratek Pharmaceuticals, Inc. 20
Immtech Pharmaceuticals, Inc. 21
Lorus Therapeutics Inc 22
Oragenics, Inc. 23
SIGA Technologies, Inc. 24
MerLion Pharmaceuticals Pte Ltd 25
Evolva SA 26
Aquapharm Biodiscovery Limited 27
MicuRx Pharmaceuticals, Inc. 28
Trius Therapeutics, Inc. 29
Escherichia Coli Infections – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
LOR-220 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antibiotic Program - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Sortase Inhibitor - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MU-1140 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Lipopeptide Programme - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
EnteroVAX - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
PM-181104 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
torezolid - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Lipopeptide Program - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MRX-I - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
WCK- 4086 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MRX-II - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SLP-0905 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SLP-0904 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Second Generation Oxas - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
EV-035 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
AQP-182 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Escherichia Coli Infections Therapeutics – Drug Profile Updates 54
Escherichia Coli Infections Therapeutics - Dormant Products 59
Escherichia Coli Infections – Product Development Milestones 60
Featured News & Press Releases 60
Sep 12, 2012: NovaBay Pharma Announces Data From New Study Demonstrating Chemical Impact Of N-chlorotaurine And NVC-422 On Bacterial Toxins 60
Sep 10, 2012: Evolva Presents Preclinical Data On EV-035 At ICAAC 60
Aug 14, 2012: Lorus Therapeutics Announces Issuance Of Patent In Japan For Antimicrobial Drug LOR-220 61
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 61
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I 62
Mar 27, 2012: Lorus Therapeutics Announces Positive Results From Small Molecule Antimicrobial Program 62
Oct 21, 2010: Lorus Therapeutics Announces Allowance Of US Patent For Lead Antimicrobial Small Molecule 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Number of Products Under Development for Escherichia Coli Infections, H2 2012 8
Products under Development for Escherichia Coli Infections – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Piramal Healthcare Limited, H2 2012 17
Nabi Biopharmaceuticals, H2 2012 18
Wockhardt Limited, H2 2012 19
Paratek Pharmaceuticals, Inc., H2 2012 20
Immtech Pharmaceuticals, Inc., H2 2012 21
Lorus Therapeutics Inc, H2 2012 22
Oragenics, Inc., H2 2012 23
SIGA Technologies, Inc., H2 2012 24
MerLion Pharmaceuticals Pte Ltd, H2 2012 25
Evolva SA, H2 2012 26
Aquapharm Biodiscovery Limited, H2 2012 27
MicuRx Pharmaceuticals, Inc., H2 2012 28
Trius Therapeutics, Inc., H2 2012 29
Assessment by Monotherapy Products, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 34
Escherichia Coli Infections Therapeutics – Drug Profile Updates 54
Escherichia Coli Infections Therapeutics – Dormant Products 59

List of Figures
Number of Products under Development for Escherichia Coli Infections, H2 2012 8
Products under Development for Escherichia Coli Infections – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 30
Assessment by Route of Administration, H2 2012 31
Assessment by Stage and Route of Administration, H2 2012 32
Assessment by Molecule Type, H2 2012 33
Assessment by Stage and Molecule Type, H2 2012 34

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos